Las Vegas, NV -- (SBWIRE) -- 10/05/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: Pfizer Inc. (NYSE:PFE), Discovery Laboratories, Inc. (NASDAQ:DSCO), Delcath Systems, Inc. (NASDAQ:DCTH), Merck & Co., Inc. (NYSE:MRK)
Pfizer Inc. (NYSE:PFE) managed to keep its gain at 0.80% on below -normal volume of 19.54M shares. The stock settled at $29 after floating in a range of $28.60 to $29.04. Its latest price has reached market capitalization of $191.99 Billion. Its 52-week range has been $23.55 to $31.15. Pfizer Inc. (Pfizer) is a research-based, global biopharmaceutical company. The Company manages its operations through five segments: Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health and Consumer Healthcare, and Nutrition.
For How Long PFE will fight for Profitability? Read This Trend Analysis report
Discovery Laboratories, Inc. (NASDAQ:DSCO) traded up on a volume of 15.23 million, higher than its standard daily volume. Shares have gained 37.06% to $2.70. Over the last twelve months, the stock has lost-17.43% and faced a worst price of $1.50. Discovery Laboratories, Inc., a specialty biotechnology company, focuses on developing products for critical care patients with respiratory disease and care in pulmonary medicine.
For How Long DSCO’s Gloss will Attract Investors? Find out via this report
Delcath Systems, Inc. (NASDAQ:DCTH) settled -2.29% lower at $0.508 on above-normal volume of 11.75M shares during the last trading day. The stock has its 12-month high at $2.38 and 52-week low price was $0.29. It traded in a range of $0.43 to $0.60 during the last trading day. Delcath Systems, Inc. operates as a specialty pharmaceutical and medical device company focusing on the field of oncology.
Will DCTH Get Buyers Even After The Recent Rally? Find Out Here
In the last trading session, Merck & Co., Inc. (NYSE:MRK) was down on low volume, trading at a volume of 11.57M versus its average daily volume of 13.94 million shares. At $48.23, the stock has attained market capitalization of 141.14 billion. Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide.
Why Should Investors Buy MRK After the Recent Fall? Just Go Here and Find Out
About Equity Observer
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/" rel="nofollow" href="http://www.equityobserver.com/"> http://www.equityobserver.com/>
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)